^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PANDA-VAC

    i
    Associations
    News

    Trials

    Company:
    UNC Lineberger Comprehensive Cancer Center
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) (NCT04266730)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Not yet recruiting
    Last update posted :
    05/07/2024
    Initiation :
    08/22/2024
    Primary completion :
    06/01/2025
    Completion :
    06/01/2033
    EGFR • ALK
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC